Research Portal

Recent advances made in the synthesis of small drug molecules for clinical applications: An insight

Research output: Contribution to journal › Article › peer-review

Standard Standard

Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. / Arora, Gunjan; Shrivastava, Ruchi; Kumar, Prashant et al.
In: Current Research in Green and Sustainable Chemistry, Vol. 4, 100097, 2021.

Research output: Contribution to journal › Article › peer-review

HarvardHarvard

Arora, G, Shrivastava, R, Kumar, P, Bandichhor, R, Krishnamurthy, D, Sharma, RK, Matharu, AS, Pandey, J & Rizwan, M 2021, 'Recent advances made in the synthesis of small drug molecules for clinical applications: An insight', Current Research in Green and Sustainable Chemistry, vol. 4, 100097. https://doi.org/10.1016/j.crgsc.2021.100097

APA

Arora, G., Shrivastava, R., Kumar, P., Bandichhor, R., Krishnamurthy, D., Sharma, R. K., Matharu, A. S., Pandey, J., & Rizwan, M. (2021). Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. Current Research in Green and Sustainable Chemistry, 4, Article 100097. https://doi.org/10.1016/j.crgsc.2021.100097

CBE

Arora G, Shrivastava R, Kumar P, Bandichhor R, Krishnamurthy D, Sharma RK, Matharu AS, Pandey J, Rizwan M. 2021. Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. Current Research in Green and Sustainable Chemistry. 4:Article 100097. https://doi.org/10.1016/j.crgsc.2021.100097

MLA

Arora, Gunjan et al. "Recent advances made in the synthesis of small drug molecules for clinical applications: An insight". Current Research in Green and Sustainable Chemistry. 2021. 4. https://doi.org/10.1016/j.crgsc.2021.100097

VancouverVancouver

Arora G, Shrivastava R, Kumar P, Bandichhor R, Krishnamurthy D, Sharma RK et al. Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. Current Research in Green and Sustainable Chemistry. 2021;4:100097. Epub 2021 Apr 22. doi: 10.1016/j.crgsc.2021.100097

Author

Arora, Gunjan ; Shrivastava, Ruchi ; Kumar, Prashant et al. / Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. In: Current Research in Green and Sustainable Chemistry. 2021 ; Vol. 4.

RIS

TY - JOUR

T1 - Recent advances made in the synthesis of small drug molecules for clinical applications: An insight

AU - Arora, Gunjan

AU - Shrivastava, Ruchi

AU - Kumar, Prashant

AU - Bandichhor, Rakeshwar

AU - Krishnamurthy, Dhileep

AU - Sharma, Rakesh Kumar

AU - Matharu, Avtar S.

AU - Pandey, Jaya

AU - Rizwan, Mohammad

PY - 2021

Y1 - 2021

N2 - Over decades dependency of humans on the drugs has become indispensable and irreplaceable. Thus, each year many new drugs are licensed. Nonetheless, drugs undergo rigorous testing and analysis to be available globally in economic price for the suitability of patients with different age and physiological conditions. The testing of drugs include phase I clinical trial using small group of 20–100 healthy volunteers for safety, pharmacology and efficacy; phase II clinical trial using 100–500 volunteer patients to optimize effective dose, dose interval, safety analysis and mode of delivery such as oral or intravenous; phase III clinical trial using 1000–5000 in a larger population of patients globally at different international places to collect sufficient safety and efficacy data for patenting and licencing. Moreover, thousands of drugs fail to achieve these objectives. Therefore, this mini-review intends to critically examine and assimilate the clinical applications of selected complex repurposed small drug molecules which are in different phase of trials for treating viral infection including complications due to COVID-19: (a) Remdesivir, (b) Galidesivir, (c) Favipiravir, (d) Baricitinib, and (e) Baloxavir.

AB - Over decades dependency of humans on the drugs has become indispensable and irreplaceable. Thus, each year many new drugs are licensed. Nonetheless, drugs undergo rigorous testing and analysis to be available globally in economic price for the suitability of patients with different age and physiological conditions. The testing of drugs include phase I clinical trial using small group of 20–100 healthy volunteers for safety, pharmacology and efficacy; phase II clinical trial using 100–500 volunteer patients to optimize effective dose, dose interval, safety analysis and mode of delivery such as oral or intravenous; phase III clinical trial using 1000–5000 in a larger population of patients globally at different international places to collect sufficient safety and efficacy data for patenting and licencing. Moreover, thousands of drugs fail to achieve these objectives. Therefore, this mini-review intends to critically examine and assimilate the clinical applications of selected complex repurposed small drug molecules which are in different phase of trials for treating viral infection including complications due to COVID-19: (a) Remdesivir, (b) Galidesivir, (c) Favipiravir, (d) Baricitinib, and (e) Baloxavir.

KW - Remdesivir

KW - Galidesivir

KW - Favipiravir

KW - Baricitinib

KW - Baloxavir

KW - Small drug molecules

KW - Drug repurposing

KW - Clinical applications

KW - COVID-19

U2 - 10.1016/j.crgsc.2021.100097

DO - 10.1016/j.crgsc.2021.100097

M3 - Article

VL - 4

JO - Current Research in Green and Sustainable Chemistry

JF - Current Research in Green and Sustainable Chemistry

SN - 2666-0865

M1 - 100097

ER -